Israel says signed MOU with NRX Pharmaceuticals for COVID vaccine trials

Israel has signed a memorandum of understanding with NRX Pharmeceuticals to complete trials and commercialize the Israeli-developed COVID-19 vaccine BriLife, Israel's Defense Ministry said on Monday.

The vaccine was developed by the Israel Institute for Biological Research, which is overseen by the Defense Ministry.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)